• Latest News
  • latest
  • Pro-life group says Trump admin didn't give key abortion drug commitments before Overton FDA nomination pulled

Pro-life group says Trump admin didn't give key abortion drug commitments before Overton FDA nomination pulled

Pro-life group says Trump admin didn't give key abortion drug commitments before Overton FDA nomination pulled

Pro-life group says Trump admin didn't give key abortion drug commitments before Overton FDA nomination pulled

A leading pro-life group said it opposed advancing Heidi Overton's nomination to lead the Food and Drug Administration without commitments from the Trump administration on abortion drug policy. The White House withdrew her nomination this week amid questions about her support in the Senate.


In an interview with Fox News Digital, Erik Baptist, senior vice president of legal strategy at Susan B. Anthony Pro-Life America, said his group asked the Senate to hold up Overtons confirmation until it received "firm commitments" from the administration on two fronts regarding abortion drug policy.


Baptist said the group wants the next FDA nominee to commit to ending authorized under the Biden administration and changing how the agency studies the safety of those pills.


"Right now, were seeing more abortions in this country than before the Supreme Courts decision overturning Roe v. Wade," Baptist said. "Thats precisely because of what the Biden FDA did to authorize mail-order abortion drugs. Were seeing upwards of 15,000 abortion drugs and abortions occurring in pro-life states. Those states cant meaningfully enforce their laws while this nationwide policy is in place."



"Under the Biden-era policy, anybody can obtain these drugs online and receive them through the mail," he continued. "When I say anybody, weve seen news story after news story every week about men and other predators obtaining these drugs to coerce or poison women into taking them against their will. Until that policy changes, no pregnant woman is safe from these drugs. My question to this administration is: How many more women have to be poisoned or coerced with abortion drugs before you take action on this drug?"


Under the Biden administration, the FDA eliminated the in-person dispensing requirement for mifepristone, allowing it to be prescribed without an in-person visit by certified prescribers and dispensed by certified pharmacies through the mail.


On the group's second point of concern, Baptist said the FDA needs to conduct a new study to show the safety — or lack thereof — of mifepristone.


"The problem is that the study is significantly flawed," he said. "Its almost designed to fail and not lead to future changes to the drug regimen. We have asked for more robust data because significant information is currently lacking, including transparency into the agencys methodology and an invitation for outside experts who have studied this drug over the last few decades."


"This is something that should be bipartisan. Everybody should support better data, more transparency and outside experts who can inform an agency that has never conducted such a study before," he added.


Several pro-life groups and Republican lawmakers have urged the Trump administration to complete the FDAs safety review of mifepristone and consider reinstating safeguards, while some have called for removing the drug from the market.


The FDA said the review is ongoing, with study results expected in December 2026 and a final report expected by March 2027.


The White House pulled Overtons nomination to lead the FDA earlier this week, one day before a Senate committee vote. President Donald Trump picked Overton, a physician and White House advisor, in August to succeed Marty Makary, who resigned from the position in May.


Kyle Diamantas has led the agency in an acting capacity since .


WOMAN WHO SAYS ABORTION PILLS NEARLY KILLED HER URGES RFK JR TO ACT AS GROUP DEMANDS MAIL-ORDER CRACKDOWN


Overton also previously served as vice chair and chief policy officer at the America First Policy Institute, a conservative think tank, where she criticized expanded access to abortion pills in a 2023 policy bri

  • Share on:

Weather

c

Humidity: %

AirKph

image title here

Some title